TAIKO PHARMACEUTICAL CO., LTD. Logo

TAIKO PHARMACEUTICAL CO., LTD.

Manufactures OTC gastrointestinal medicine and leading infection control products.

4574 | T

Overview

Corporate Details

ISIN(s):
JP3442200006
LEI:
Country:
Japan
Address:
吹田市内本町三丁目34番14号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Taiko Pharmaceutical Co., Ltd. is a manufacturer and distributor specializing in pharmaceuticals and infection control products. The company operates through three primary business segments: Pharmaceutical, Infection Control, and Others. Its Pharmaceutical division is centered on its flagship product, Seirogan, an over-the-counter gastrointestinal medication with a history of over 100 years, used for treating symptoms like diarrhea and loose stools. The Infection Control division, a significant contributor to company revenue, develops and markets products including a leading brand of airborne disinfectants. The company is engaged in ongoing research and development to support its product lines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:35
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-08-08 08:34
Interim Report
半期報告書-第80期(2025/01/01-2025/12/31)
Japanese 197.8 KB
2025-04-01 08:45
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2025-03-28 07:36
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2025-03-28 07:35
Governance Information
内部統制報告書-第79期(2024/01/01-2024/12/31)
Japanese 22.1 KB
2025-03-28 07:33
Registration Form
確認書
Japanese 8.1 KB
2025-03-28 07:32
Annual Report
有価証券報告書-第79期(2024/01/01-2024/12/31)
Japanese 1011.8 KB
2024-08-09 08:34
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-08-09 08:33
Interim Report
半期報告書-第79期(2024/01/01-2024/12/31)
Japanese 210.9 KB
2024-05-10 08:37
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-05-10 08:35
Quarterly Report
四半期報告書-第79期第1四半期(2024/01/01-2024/03/31)
Japanese 164.9 KB
2024-04-01 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-03-28 07:30
Governance Information
内部統制報告書-第78期(2023/01/01-2023/12/31)
Japanese 22.1 KB
2024-03-28 07:28
Registration Form
確認書
Japanese 8.1 KB
2024-03-28 07:26
Annual Report
有価証券報告書-第78期(2023/01/01-2023/12/31)
Japanese 1.1 MB

Automate Your Workflow. Get a real-time feed of all TAIKO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAIKO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAIKO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGEN CORP Logo
Provides diagnostic tests and genomics services for food, animal, and agricultural safety.
United States of America
NEOG
NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS

Talk to a Data Expert

Have a question? We'll get back to you promptly.